Glaxosmithkline Pharmaceuticals Limited · NSE:GLAXO

Glaxosmithkline Pharmaceuticals — Q2 FY27 Earnings Presentation

9 slides from Glaxosmithkline Pharmaceuticals's earnings presentation, Nov 4, 2026

  1. Slide 1: Presentation of Analyst / Institutional Investor Meetings

    GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 4th November 2026 To, BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exc

  2. Slide 2: GlaxoSmithKline Pharmaceuticals Limited

    GlaxoSmithKline Pharmaceuticals Limited gsk.com

  3. Slide 3: Bhushan Akshikar, Managing Director; Ronojit Biswas, Chief Financial Officer

    Bhushan Akshikar, Managing Director Mr. Bhushan Akshikar has been the MD of GSK India since Q3 2022. He brings over 15 years of leadership experience within GSK in key roles across India, Middle East, Russia CIS & Africa region. Prior to joining GSK, Bhushan spent 15 years with Johnson & Johnson, in

  4. Slide 4: GSK India's key focus areas to drive growth aligned to global priorities

    GSK India’s Key Focus areas to drive growth aligned to global priorities Deliver Accelerate Simplify how growth R&D we work Established portfolio – deliver Focus on innovation & accelerate Reduce complexity, focus resources on competitive performance; launch of pipeline products what matters most an

  5. Slide 5: IPM Q2 FY27 grew at 14.7%, GSK continued its momentum

    IPM Q2 FY27 grew at 14.7%, GSK continued its momentum IPM sees growth largely on account Within Acute, key therapies like AI, Respi GSK’s Rep market grew at 11% with Gen GSK’s performance in metro class and of price. grew at 7% & 5% resp. Med outperforming the market specialties outgrew the market G

  6. Slide 6: GSK's key brands remained competitive in the market in Q2 FY27

    GSK’s key brands remained competitive in the market in Q2 FY27 GENERAL MEDICINES VACCINES SPECIALTY Gen Meds1 market share improved (+2.1% Building equity in the 1 2 Established Vaccines continues to lead the 4 Unit MS gain, Unit EI 105); key brands overall Vx market with 21.5% Val MS2 Unit EI Respi

  7. Slide 7: Financial Highlights: Q2 FY 26-27 (Standalone)

    Financial Highlights : Q2 FY 26-27 (Standalone) Delivering growth with continued portfolio transformation Revenue EBITDA PAT (before exceptional) Q2 H1 Q2 H1 Q2 H1 ₹1180cr ₹2104cr ₹400cr ₹693cr ₹335cr ₹588cr Growth +21% Growth +18% Margin: 34% (-50 bps) Margin: 33% (+10 bps) Margin: 29% (+260 bps) M

  8. Slide 8: Consistent competitive performance and profitability improvement with portfolio transformation

    Consistent competitive performance & profitability improvement with portfolio transformation 35.9 35.2 Improving profitability 34.4 33.9 34.3 Portfolio transformation 31.7 31.9 30.7 31.2 28.5 Upcoming Launches 28.3 28 27 24.3 Q3 FY22 Q3 FY23 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2

  9. Slide 9: End of Presentation

    gsk.com End of Presentation

GlaxoSmithKline Pharmaceuticals — Q2 FY27 Earnings Presentation on 6ix